PRKAA2 and metabolic dysfunction-associated steatotic liver disease: Further investigations revealed that APS alleviates MASLD in rats by rebalancing gut microbiota homeostasis, which in turn suppresses serum proinflammatory cytokines (e.g., TNF-α, IL-6) and activates the AMPK-PPAR-α signaling axis to inhibit de novo lipogenesis (Zhong et al., 2022).